Lutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.
Adjuvant pembrolizumab reduced the risk of disease recurrence or death, but did not improve overall survival, compared with observation in patients with urothelial carcinoma.
"Patients shouldn’t be making the decision to do active surveillance without understanding what that means and what their other options are,” one panelist said.
“There’s a lot of clinical trial activity in the [bladder cancer realm], and hopefully [new therapies will] keep adding to our armamentarium of [treatment strategies] we can offer patients,” said Gautam Jayram, MD.
Treatment with the first-line combination of pembrolizumab and lenvatinib led to durable anti-tumor activity in patients with non–clear cell renal cell carcinoma.
Preliminary findings from the single-arm, phase 2 CORE-001 trial showed that the combination of the oncolytic immunotherapy cretostimogene grenadenorepvec (CG0070) and pembrolizumab (Keytruda) elicited a high complete response rate in patients with BCG–unresponsive non–muscle invasive bladder cancer.
“The combination of sintilimab and axitinib had a manageable safety profile and achieved a promising tumor response rate in patient with advanced FH-deficient RCC,” said Xingming Zhang.
“We hypothesized that the combination of guadecitabine plus durvalumab would increase T lymphocyte infiltration and result in antitumor activity,” said lead study author Yousef Zakharia, MD.
At a median follow-up of 13.4 months, 336 (75%) OS events occurred with atezolizumab plus platinum and gemcitabine and 310 (78%) occurred with placebo plus platinum and gemcitabine.
“These findings are hypothesis-generating and suggest a possible therapeutically synergistic role for immune checkpoint blockade in [patients with] BCG-unresponsive NMIBC who may have partial or short-term response to nadofaragene treatment,” said lead study author Anirban P. Mitra, MD, PhD.
Published: April 14th 2023 | Updated:
